Combination of Hydroxy-Methylglutaryl-Coenzyme-A-Reductase Inhibitors (HMG-CoA-Reductase) and Mammalian Rapamycin Target Inhibitors (MRM)

摘要

1. A pharmaceutical combination comprising a β-hydroxy-β-methylglutaryl-coenzyme-A reductase inhibitor (HMG-CoA reductase), especially fluvastatin or pitavastatin, or a pharmaceutically acceptable salt thereof, and a mammalian rapamycin target inhibitory agent (MRM- inhibitory agent). ! 2. The pharmaceutical combination according to claim 1, wherein the inhibitor of HMG-CoA reductase is fluvastatin or a pharmaceutically acceptable salt thereof. ! 3. The pharmaceutical combination according to claim 1, wherein the inhibitor of HMG-CoA reductase is pitavastatin or a pharmaceutically acceptable salt thereof. ! 4. The pharmaceutical combination according to one of claims 1 to 3, in which the MPM inhibitory agent is selected from rapamycin or a rapamycin derivative selected from the group consisting of: 32-deoxorapamycin, 16-pent-2-ynyloxy-32-deoxy-rapamycin, 16- pent-2-ynyloxy-32 (S or R) -dihydrorapamycin, 16-pent-2-ynyloxy-32 (S or R) -dihydro-40-O- (2-hydroxyethyl) -rapamycin, 40- [3-hydroxy -2- (hydroxymethyl) -2-methylpropanoate] -rapamycin (also designated CCI779), 40-epi- (tetrazolyl) -rapamycin (also referred to as ABT578), 40-O- (2-hydroxyethyl) -rapamycin, 32-deoxorapamycin and 16-pent-2-ynyloxy-32 (S) -dihydr orapamycin or a pharmaceutically acceptable salt of the rapamycin derivative for simultaneous, sequential or separate use. ! 5. The pharmaceutical combination according to claim 1, comprising pitavastatin or a pharmaceutically acceptable salt thereof and 40-O- (2-hydroxyethyl) rapamycin for simultaneous, sequential or separate use. ! 6. The pharmaceutical combination according to claim 1, comprising fluvastatite or a pharmaceutically acceptable salt thereof and 40-O- (2-hydroxyethyl) -rapamycin for simultaneous, sequential or multiple times